

## **Date of AGM and Closing Date for Director Nominations**

**Melbourne, Australia; 18 September 2023:** Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Monday, 13 November 2023.

An item of business at the AGM will be the re-election of directors. In accordance with clause 8.1 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Monday, 25 September 2023.

Any nominations must be received by the Company no later than 5:00 pm (Melbourne time) on Monday, 25 September 2023.

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [littlebigdealconsulting@gmail.com](mailto:littlebigdealconsulting@gmail.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**